Drug Information

Updated On: 27-02-2024

Home

About Us

FAQs

Feedback

Disclaimer

Site Map

Home > Search > > Drug Information

Mefloquine ( * ) - @ - 4- Aminoquinolne derivatives- (March 1997)

Drug Name:
Mefloquine ( * ) - @ - 4- Aminoquinolne derivatives- (March 1997)

List Of Brands:

MEFLOTAS
LARIMEF

Indication Type Description:

Drug Interaction

Indication

Adverse Reaction

Contra-Indications

Dosages/ Overdosage Etc

Other Information

Patient Information

Pharmacology/ Pharmacokinetics

Pregnancy and lactation

Drug Interaction:

Interacting drugs-summary

Mefloquine +

Beta-adrenergic blockers

ECG abnormalities or cardiac arrest occur with concurent mefloquine

Chloroquine-

Risk of convulsons increased with concomittant mefloquine

Quinine/Quinindine-

do not use concurrently with mefloquine. If they are to used for severe

malaria, delay mefloquine administration for 12 hours after last dose of

quinine or quinidine.

ECG abnormalities or cardiac arrest occur.

Valproic acid-

concurrent mefloquine resulted in loss of seizure control and lower than

expected valproic blood levels. Monitor valproic acid blood levels

Indication:

Malaria

Approved by (DCI) Drug Controller GENERAL - India For Marketing

(Ref- IDMA Publication)

Name of Drug Indication Date of Approval

Mefloquine Hcl Anti Malarial 03-03-1997

Adverse Reaction:

Vomiting, dizziness, syncope, extrasystole. Vertigo, visual disturbances, CNS disturbances. Nyalgia. nausea, fever, headache, vomiting, chills, diarrhea, skin rash, abdominal pain, fatigue, loss of appetite, tinnitis.

Contra-Indications:

Hypersensitivity to mefloquine

Special precautions:

Monitor liver function tests. Ocular lesions.

Hazardous tasks- caution while performing hazaardous tasks, driving.

Dosages/ Overdosage Etc:

Malaria

Dosage-

Adult- 20-25mg/kg as a single dose or preferably in 2 or 3 divided doses at 6-8 hours interval Prophylaxis of malaria- adult- 250mg taken 1-3 weeks before exposure and continuing for 4 week after leaving the malaria area

Other Information:

For Availability/supplies

Contact -

1.Indian Drug Manufacturers Association (IDMA)

Phone- 022- 24944624/ 24974308

Fax- 022- 24950723

Email- idma@vsnl.com

Website: www.idma-assn.org

2.Bulk Drug Manufacturers Association (India)(BDMA)

Phone - 040-23703910/ 23706718

Fax- 040-23704804

Email- info@bdmai.org

Website: www.info@bdmai.org

Patient Information:

Ref - USP PDI Vol II 17th Edition (1997)

1.Allergies-

Tell your doctor if you have ever had any unusual or allergic reaction to

Mefloquine,quinidine, quinine, or related medicine. Also tell your healthcare

care professional if you are allergic to any other substances such as foods,

preservatives or dyes.

2.Pregnancy-

Mefloquine has not been studied in pregnant women, and its use is not

recommended during pregnancy.

3. Breast-feeding-

Mefloquine passes into breast milk in small amounts.

4.Children-

Studies of mefloquine use in children has shown that medicine causes

side effects in children like those seen in adults eg nausea, vomiting and

diarrhea. Its use is not recommended in infants and children

5.Older adults-

There is no specific information comparing use of mefloquine in the elderly

with use in other age groups

6. Other medicines-

Tell your doctor if you are using any of the following-

Bepridil or

Beta-blokers or

Diltiazem or

Flunarazine

Nicardipine or

Quinidine or

Verapramil - use of these medicines together with mefloquine may result

in slow heart beat and other heart problems - Increased chance of seizures

may occur when quinine is taken with mefloquine

7. Other medical problems-

Make sure you tell your doctor if you have any other medical problems

especially-

Convulsuions or

Eliplepsy or

Heart block or

Psychiatric disorders- mefloquine may make these conditions worse.

Pharmacology/ Pharmacokinetics:

Pharmacology:

Mefloquine is an antimalarial agent which acts as a blood schizoticide. Mechanism of action is not well known. It is astructural analog of quinine.

Pregnancy and lactation:

Pregnancy:

Use during pregnancy only if potential benefits outweigh potential risk to the fetus.

Lactation:

Excercise caution while administering mefloquine to nursing woman.

Children:

Safety and efficacy are not established.

Search

Look In

Keyword

Mode

	Starts With		Contains

Quick Links

Home
About Us
FAQs
Disclaimer
Site Map

Free Mobile App

About Us

FAQs

Feedback

Disclaimer: Every effort has been made to ensure that the information provided in this Database is authentic and accurate. Commissions or omissions in the database, if any, are purely inadvertent and the site owner shall not accept any liability whatsoever for any adverse consequences of any nature arising to any individual or third party, as a result of usage of this information.